MR evaluation CNS tumors comparison study gadopentetate dimeglumine gadoteridol phase II III trials gadoteridol new nonionic low-osmolar contrast agent patients intracranial neoplasms underwent magnetic resonance MR experimental doses mmol/kg Fifteen patients underwent contrast studies standard dose mmol/kg gadopentetate dimeglumine gadopentetate dimeglumine gadoteridol similar effect equal doses mmol/kg Lesion enhancement delineation experimental doses mmol/kg experimental dose mmol/kg Quantitative analysis lesions identical imaging protocols proportional relationship lesion contrast ratio dose range mmol/kg Phantom experiments clinical results Improved enhancement detection delineation central nervous system CNS injected doses gadoteridol potential significant possibly cost contrast material dosage doses adequate evaluation CNS tumors 